Florian Maria WurmFlorian Wurm received his academic training as a Biologist and Molecular Geneticist at the University of Giessen. He joined the Hoechst AG (Behringwerke) in Marburg as head of a laboratory in Virology. Working with immortalized mammalian cells for the establishment of production processes for alpha-interferons provided the first opportunity to combine basic research with medical application. In 1984 he joined Harvard Medical School in Boston as a Research Fellow in Molecular Biology. 1986 he took an offer from Genentech Inc. in San Francisco to work in Process Sciences on the development of large scale manufacturing processes for recombinant proteins. There he has held a number of leading positions and has acquired intimate knowledge in the generation of protein pharmaceuticals in mammalian cells in bioreactors (a number of which are now marketed products). In 1995 he joined the EPFL as a Professor for Biotechnology. Wurm has published more than 250 scientific papers and holds more than 20 patents/patent-applications. His H-index stands at 60 in 2021. He was Chairman (2005-2009) and is member of the Executive Board of the European Society of Animal Cell Technology (ESACT). He serves as a consultant to the pharmaceutical Biotech Industry, mainly in the fields of animal cell technology for recombinant protein production and in regulatory affairs. He works as a scientific reviewer and editior/asscciate editor for a number of international journals in the Biotech field. F.M. Wurm teaches classes to pre- and postgraduate students in the fields of Molecular and Cellular Biotechnology.
He was founder and Chief Scientific Officer of ExcellGene SA, a 2001 established company in Monthey, Switzerland. He took the position of President and CEO of ExcellGene in 2015. He retired from the CEO position in 2017 and continues to be President and Chief Scientific Officer of ExcellGene.
In 2008 Dr. Wurm was appointed Visiting Professor for Biotechnology at Jinan University in Guangzhou, China. He retired from his position at the EPFL in 2015. His laboratory is closed. With his team at ExcellGene and in collaboration with Dr. Paco Pino, Director of R&D, he continues to explore manufacturing sciences with animal cells in bioreactors.
Horst VogelHorst Vogel est né en 1948 à Würzburg, Allemagne. Après ses études en chimie, il obtient le diplôme de chimie en 1974 de l'Université de Würzburg.Il entreprend ensuite un travail de doctorat au Max-Planck Institut für Biophysikalische Chemie de Göttingen, et obtient en 1978 le grade de docteur ès sciences de l'Université de Göttingen. De 1978 à 1983 il effectue des recherches au Max-Planck Institut für Biologie à Tübingen et en 1984, il rejoint le Biocentre à Bâle où il travaille jusqu'en 1989, effectuant une année au Karolinska Institute à Stockholm. En 1989, Horst Vogel rejoint l'institut de chimie physique de l'EPFL où il dirige un groupe travaillant dans les domaines de la biophysique et de la bioélectronique.
Depuis le 1er octobre 1994 il est profeseur en chimie physique des polymères et membranes au Département de chimie de EPFL. Ses intérêts de recherche sont l'étude de la structure et de la dynamique de récepteurs membranaires et l'auto-assemblage des biomolécules aux interfaces pour développer de nouveaux biocapteurs dans le domaine de micro- et nanotechnologie. Il enseigne les sciences du vivant, la biophysique et biochimie, et des chapitres concernant la biotechnologie.
Dipl. in Chemistry1974-Univ. Würzburg, DE
Ph.D.-1978-MPI für Biophys. Chemie, Göttingen, DE
Theo LasserDe nationalité allemande, né en 1952 à Lauchheim (Baden-Württemberg). Après des études de physique à l'Université Fridericiana de Karlsruhe, il y obtient son diplôme de physique en 1978.
En 1979, il rejoint l'Institut de Recherches franco-allemand à Saint-Louis (France) comme collaborateur scientifique. En 1986, il rejoint la division de recherche de Carl Zeiss à Oberkochen (Allemagne) où il développe principalement divers systèmes laser pour des applications médicales. Dès 1990, il dirige le laboratoire laser de la division médicale. En 1993, il prend la direction de l'unité "laser d'ophtalmologie". Dès le début 1995, il est chargé de restructurer et regrouper les nombreuses activités d'ophtalmologie chez Carl Zeiss et de les transférer à Jena. Durant cette période, il réalise des nouveaux instruments de réfraction, des biomicroscopes et des caméras rétiniennes.
Dès janvier 1998, il dirige la recherche de Carl Zeiss à Jena où il initie de nouveaux projets en microscopie, en microtechnique et en recherche médicale. En juillet 1998, il est nommé professeur ordinaire en optique biomédicale à l'Institut d'optique appliquée. Au sein du Département de microtechnique, son activité de recherche porte sur la photonique biomédicale. Il participe à l'enseignement d'optique et d'instrumentation biomédicale.
Short CV
1972 Physics University of Karlsruhe (Germany)
1979 l'Institut de Recherches franco-allemand à Saint-Louis (France)
1986 central research division Carl Zeiss, Oberkochen (Germany)
1990 Med - Division, ophthalmic lasers
1994 Ophthalmology division, Carl Zeiss Jena
1998 Head of Central research Carl Zeiss Jena
1998 full Professor Ecole Polytechnique Federale Lausanne, Switzerland
Georges WagnièresGeorges Wagnières received his diploma degree (MSc) in physics from the University of Lausanne, Switzerland, in 1986. He obtained his doctorate in science (PhD) in physics (Biomedical optics) from the Swiss Federal Institute of Technology at Lausanne (EPFL) in 1992 and did a postdoctoral work in the Wellman Laboratories of Photomedicine (Harvard Medical School), Boston, USA, from 1993 to 1994. He also obtained a Master degree in Management of Technology delivered by the Ecole des Hautes Etudes Commerciales (HEC) of Lausanne University and the EPFL in 2001. Georges Wagnières manages a research group active in the fields of: - Detection of early superficial cancers by fluorescence imaging. - Characterization of early superficial cancers by high magnification narrow band imaging. - In vivo and in vitro measurement of the vascular and tissular oxygen concentration by time-resolved luminescence spectroscopy and imaging. - Preclinical and clinical study of new photosensitizers for photodynamic therapy (PDT). - Treatment of neurodegenerative conditions (Alzheimer, Parkinson's diseases) by photobiomodulation. - Preclinical and clinical photodynamic therapy of inflammatory bowel diseases and atheroscerotic plaque. - Improvement of the selective vascular extravasation of chemotherapeutic agents by PDT. - Monitoring the light dosimetry during PDT by fluorescence spectroscopy and imaging. - Monitoring laser treatments of the retina by reflectance imaging. - Light dosimetry and tissue optical spectroscopy. - Radiometry. - Development of light delivery systems for biomedical applications. Georges Wagnières is also co-founder and was chairman of one spin-off companies: - Medlight SA, founded in July 1997, which develops, produces and commercializes light distributors for photodynamic therapy. Georges Wagnières has currently authored more than 235 papers (more than 150 in international journals with review board) and is inventor of 18 patents. He supervised 12 PhD students up to now, and currently teaches biomedical optics and photomedicine in master programs and doctoral schools. In addition, he gives the course entitled "Physique Générale I" to biology first year students registered to the Biology School of the Lausanne's University. MAIN PUBLICATIONS Please visit: https://www.epfl.ch/labs/lifmet/wagnieres/publications/ Pablo Rivera FuentesPablo Rivera-Fuentes was born in 1984 in Mexico City. He received a BSc (2008) degree in chemical engineering from the National Autonomous University of Mexico. He obtained his MSc (2009) and PhD (2012) degrees in chemistry from ETH Zurich, working under the supervision of Prof. François Diederich. His dissertation was awarded the ETH Medal in 2013. Funded by the Swiss National Science Foundation (SNSF), he carried out postdoctoral research at Massachusetts Institute of Technology with Prof. Stephen J. Lippard (2012-2014). He subsequently worked at the University of Oxford with Prof. Harry L. Anderson (Department of Chemistry) and Prof. Christian Eggeling (Weatherall Institute of Molecular Medicine). He started his independent career as non-tenure-track assistant professor at ETH Zurich in October, 2015, and became tenure-track assistant professor of chemical biology at EPFL in August, 2019.
Didier TronoAfter obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
Martinus GijsMartin A.M. Gijs received his degree in physics in 1981 from the Katholieke Universiteit Leuven, Belgium and his Ph.D. degree in physics at the same university in 1986. He joined the Philips Research Laboratories in Eindhoven, The Netherlands, in 1987. Subsequently, he has worked there on micro-and nano-fabrication processes of high critical temperature superconducting Josephson and tunnel junctions, the microfabrication of microstructures in magnetic multilayers showing the giant magnetoresistance effect, the design and realisation of miniaturised motors for hard disk applications and the design and realisation of planar transformers for miniaturised power applications. He joined EPFL in 1997. His present interests are in developing technologies for novel magnetic devices, new microfabrication technologies for microsystems fabrication in general and the development and use of microsystems technologies for microfluidic and biomedical applications in particular.
